Research News

---

Topic: Hormonal Therapies (view all topics)

Tags for topic Hormonal Therapies:

• After surgery (also called "adjuvant")
• Arimidex
• Aromasin
• Aromatase Inhibitors
• Before surgery (also called "neoadjuvant")
• Evista
• Fareston
• Faslodex
• Femara
• Not applicable (no surgery)
• Planning Hormonal Therapy
• Prophylactic (to lower risk if you've never been diagnosed with breast cancer)
• Selective Estrogen Receptor Modulators
• Tamoxifen

View articles by month and year

• Higher Faslodex Dose Better for Recurrent or Metastatic Breast Cancer

  Published on December 17, 2012 at 9:34 am

  • Tags: Faslodex

  A study has found that women diagnosed with recurrent or metastatic, hormone-receptor-positive breast cancer lived longer when they got 500 mg of Faslodex compared to women who got 250 mg of Faslodex.

• Combination of Arimidex and Faslodex Better Than Arimidex Alone to Treat Metastatic Breast Cancer

  Published on September 12, 2012 at 12:00 am

  • Tags: Arimidex, Faslodex, Not applicable (no surgery), and Planning Hormonal Therapy

  A study has found that postmenopausal women diagnosed with hormone-receptor-positive metastatic breast cancer and treated with a combination of Arimidex and Faslodex as the first treatment for metastatic disease lived about 6 months longer than women treated only with Arimidex.

• Arimidex-Faslodex Combo Improves Survival in Metastatic Breast Cancer

  Published on December 8, 2011 at 12:00 am

  • Tags: Arimidex, Faslodex, and Planning Hormonal Therapy

  A study has found that postmenopausal women diagnosed with hormone-receptor-positive metastatic breast cancer and treated with a combination of Arimidex and Faslodex as the first treatment for metastatic disease lived 6 months longer than women treated only with Arimidex.

• Higher Faslodex Dose More Effective Against Metastatic Breast Cancer

  Published on December 14, 2009 at 12:00 am

  • Tags: Arimidex, Faslodex, and After surgery (also called "adjuvant")

  Advanced-stage, hormone-receptor-positive breast cancers treated with 500 mg of Faslodex (double the usual dose) had a slightly better response than cancers treated with 250 mg of Faslodex (the usual dose).